A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

Clinical Trial ID NCT01761266

Rank	Title	Journal	Year	PubWeight™‹?›
1	Drug therapy for advanced-stage liver cancer.	Liver Cancer	2014	1.03
2	Clinical trials in hepatocellular carcinoma: an update.	Liver Cancer	2013	0.99
3	Drug development: try and try again.	Nature	2014	0.88
4	Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer.	Ther Adv Med Oncol	2014	0.80
5	Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?	World J Gastrointest Oncol	2016	0.80
6	Therapeutic targeting of fibroblast growth factor receptors in gastric cancer.	Gastroenterol Res Pract	2015	0.77
7	Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?	World J Gastroenterol	2016	0.76
8	Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma.	J Hepatocell Carcinoma	2014	0.75
9	Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma.	J Hepatocell Carcinoma	2016	0.75
10	The Use of Genetic Alterations in the Development of Liver Cancer Drugs.	Gastroenterol Hepatol (N Y)	2015	0.75
11	Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma.	Front Pharmacol	2016	0.75